Patna: An academic programme on cardiovascular disease held at Ford Hospital Patna this week brought renewed optimism for heart failure patients, as an international expert shared updates on an emerging drug currently under clinical evaluation.
Addressing a gathering of physicians and cardiologists, Dr David Sim, a senior specialist associated with the National Heart Centre Singapore, outlined the importance of a comprehensive approach to heart failure care. He stressed that treatment should not end at hospital discharge, but must extend into structured follow-up, lifestyle modification and strict adherence to medication in order to reduce complications and improve survival rates.
Dr Sim told attendees that he is part of a clinical trial team working on a new drug aimed at slowing or preventing the progression of heart failure. While details of the compound remain under study, he said early findings suggest the therapy is moving in a “positive direction”. If approved, the drug could offer a safer and more effective option for patients living with the chronic condition, potentially improving quality of life and lowering hospital readmission rates.
Chairing the session, Dr B B Bharti described heart failure as a growing public health burden, particularly in developing regions where late diagnosis remains common. He emphasised that timely detection, optimal pharmacological management and regular follow-up are essential to preventing deterioration. The hospital, he added, is investing in modern technology and specialist expertise to strengthen cardiac services.
The discussion was moderated by interventional cardiologist Dr Sushant Kumar Pathak, who said academic exchanges of this kind help local doctors stay aligned with evolving global guidelines. He noted that collaborative learning and evidence-based care models ultimately translate into better outcomes for patients facing heart failure.
